Medifast (NYSE: MED) reported Q2 EPS of $0.22, $0.44 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $105.6 million versus the consensus estimate of $96.1 million.

GUIDANCE:

Medifast sees Q3 2025 EPS of ($0.60)-$0.00, versus the consensus of ($0.30). Medifast sees Q3 2025 revenue of $70-90 million, versus the consensus of $93.8 million.

For earnings history and earnings-related data on Medifast (MED) click here.